Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study

Myelodysplastic syndrome (MDS) with TP53 mutations has a poor prognosis after transplantation, and novel therapeutic means are urgently needed. Decitabine (Dec) monotherapy has demonstrated improved overall response rates in MDS and acute myeloid leukaemia, although these responses were not durable....

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yuxin, Sun, Yao, Xie, Jing, Hu, Jiangwei, Liu, Na, Chen, Jianlin, Li, Botao, Lan, Sanchun, Niu, Jingwen, Wang, Lei, Qiao, Zhuoqing, Zhang, Yu, Ren, Jing, Zhang, Bin, Qian, Liren, Tan, Yehui, Dou, Liping, Li, Yuhang, Hu, Liangding
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339648/
https://www.ncbi.nlm.nih.gov/pubmed/35924157
http://dx.doi.org/10.3389/fonc.2022.928324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339648/
https://www.ncbi.nlm.nih.gov/pubmed/35924157
http://dx.doi.org/10.3389/fonc.2022.928324

Ejemplares similares